GlassScriptPhysician profile
Adam C Bales
NPI 1043654429
$1,028.05
in general payments reported to CMS, 2019-2025
7 companies · $491 in 2025
The $491 reported for 2025 was more than what 91% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $14.10 · 2021: $38.22 · 2022: $15.65 · 2023: $24.79 · 2024: $444 · 2025: $491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $960.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $960.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $799.16 | 2023-2025 | Watchman Flx, Farapulse, Watchman Access System |
| Merck Sharp & Dohme LLC | $67.97 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $63.80 | 2025 | |
| Medtronic, INC. | $33.34 | 2025 | In.Pact Admiral |
| Penumbra, INC. | $23.75 | 2025 | Indigo System |
| Heron Therapeutics, INC. | $20.55 | 2024 | Aponvie |
| Silk Road Medical, INC. | $19.48 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Bales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.